Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer (METRO)

Vastra Gotaland Region

Status: Completed

Conditions: Chemotherapy Effect; Breast Cancer Metastatic

Treatments: Drug: Capecitabine, Cyclophosphamide

Study type: Observational

Funder types: Other

Identifiers

NCT04350021

2018-09-20 Version 1.2

Details and patient eligibility

About

Low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC) is used as a palliative regiment with the aim to prolong and improve quality of life. The effect of LDMC is not fully elucidated. The aim is to evaluate the effect of LDMC with Capecitabine and Cyclophosphamide (CX) and to discover new potential predictive markers and potential markers for monitoring treatment effect.

Enrollment: 40 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written and informed consent
• Breast cancer confirmed by histology
• Recurrence (local or distant) not possible to cure
• Measurable or evaluable disease
• Life expectancy of more than tree months
• ECOG (Eastern Cooperative Oncology Group) performance 0-2
• No or any lines of previous therapies for recurrent disease.
• Adequate contraception for patients of Child bearing age.

Exclusion criteria

• Clinically significant cardiovascular disease
• Non healing wound, Active peptic ulcer or bone fracture
• Evidence of any other disease that puts the patient at high risk for treatment-related complications